Logo Medical XPRT
Companies
Products
Services
Software
Training
Applications
Sign in
List your business

Advertising options
  1. Home
  2. News
  3. phenotype
Show results for
Products
Services
Software
Applications

Companies

News
Articles
Books
Magazines
Downloads
Videos

Refine by
Date

  • This Year
  • Older

Phenotype Articles & Analysis

105 news found

CD Bioparticles Launches Advanced Bio-Targeted Small Molecules Conjugated Magnetic Nanoparticles for Targeted Cancer Therapy

CD Bioparticles Launches Advanced Bio-Targeted Small Molecules Conjugated Magnetic Nanoparticles for Targeted Cancer Therapy

Combined with nanotechnology, "smart" drugs can actively target tumors by binding to corresponding receptors on tumor cells through interactions with phenotype-specific ligands conjugated to the delivery vehicle. Additionally, binding to certain receptors can trigger internalization and help avoid the development of resistance mechanisms. ...

ByCD Bioparticles


Creative Diagnostics Announces Antiviral Drug Discovery Services to Accelerate Therapeutic Development

Creative Diagnostics Announces Antiviral Drug Discovery Services to Accelerate Therapeutic Development

Hit identification and optimization Creative Diagnostics provides comprehensive support for drug screening using virtual, biochemical, biophysical, cellular and phenotyping platforms. The company offers phenotyping, biochemical and cellular assays for microbial and cellular growth inhibition in recombinant human cells or primary cells, bacteria, viruses, yeast ...

ByCreative Diagnostics


Understanding Lung Biomechanics In Asthma By Combining ex vivo with in vivo

Understanding Lung Biomechanics In Asthma By Combining ex vivo with in vivo

Asthma remains a complex and multifactorial disease, with airway hyperresponsiveness to methacholine being a hallmark feature. A recent study by Rojas-Ruiz et al (2025) utilizes SCIREQ’s innovative physioLens (ex vivo) and flexiVent (in vivo) platforms to shed light on the interplay between lung tissue compliance and methacholine response, offering new insights into the mechanisms ...

BySCIREQ - an emka TECHNOLOGIES Company


Advancing Tuberculosis Treatment: The Role of flexiVent In Evaluating Bacteriophage Therapy

Advancing Tuberculosis Treatment: The Role of flexiVent In Evaluating Bacteriophage Therapy

The rise of antibiotic-resistant bacteria has driven renewed interest in alternative treatments, including phage therapy. A recent study by Yang, F., et al (2024) explores the potential of bacteriophage therapy for treating multi-drug resistant Mycobacterium tuberculosis (Mtb) infections using humanized mouse models. This study highlights the efficacy of phage DS6A in reducing Mtb load ...

BySCIREQ - an emka TECHNOLOGIES Company


CD BioSciences Launches New 3D Tissue Imaging Services

CD BioSciences Launches New 3D Tissue Imaging Services

Its state-of-the-art laboratory equipment and techniques allow scientists to perform 3D imaging and phenotyping of cell populations throughout the depth of the tissue for biological research. ...

ByCD BioSciences


BIOtechNOW featured IVS’s participating BIO Innovation Zone

BIOtechNOW featured IVS’s participating BIO Innovation Zone

Ayla Annac, InvivoSciences: InvivoSciences (IVS) is a leading developer of proprietary, award-winning platform technologies that creates human 3D cell/tissue culture models and their automated phenotype analyzers for drug discovery and precision medicine development. ...

ByInvivoSciences, Inc. (IVS)


BIO Investor Forum Company Snapshot: InvivoSciences

BIO Investor Forum Company Snapshot: InvivoSciences

(IVS) is a leading developer of proprietary human 3D cell/tissue culture models for highly-predictive, multi-parameter phenotypic assays both in pharmacology safety & discovery screening and in personalized and regenerative medicine. ...

ByInvivoSciences, Inc. (IVS)


How Technology, Early Diagnoses Can Help Turn the Tide on Prostate Cancer Prognosis

How Technology, Early Diagnoses Can Help Turn the Tide on Prostate Cancer Prognosis

” They then used conditional logistical regression by estimating the association of metabolite patterns with prostate cancer risk. Metabolic Phenotyping Can Bolster Fight Against PC From a metabolic research stance, PC is very different from other cancers because prostatic tissue shows high metabolic activity. ...

ByLifespin GmbH


Why Knowledge Is Power In The Treatment Of Obesity

Why Knowledge Is Power In The Treatment Of Obesity

Dr. Ali Tinazli is the CEO of lifespin.health and has 15+ years in Fortune 100 corporate strategy and entrepreneurship (SONY, HP). Obesity rates continue to climb alongside a $254.9 billion global weight loss products and services market. Supplements, smartphone weight loss apps, diet plans and exercise programs are widely available to consumers, yet the World Obesity Federation projects that 1 ...

ByLifespin GmbH


CytoRecovery Awarded National Science Foundation Phase II SBIR Research Grant

CytoRecovery Awarded National Science Foundation Phase II SBIR Research Grant

The Company’s proprietary technology uniquely enables the recovery of specific live cell subpopulations without altering the cells by exploiting biophysical differences in cell phenotypes. This label-free approach improves the quality of the cell samples recovered, providing more accurate representation of human disease, and enabling their maintenance and viability for ...

ByCytorecovery, Inc.


4D Path Makes Continued Investments in Robust IT Infrastructure for Novel Precision Oncology Platform

4D Path Makes Continued Investments in Robust IT Infrastructure for Novel Precision Oncology Platform

4D Path applies universal physics, biology and mathematical principles to identify tumor-specific phenotypic and genotypic fingerprints. Its system runs on modern cloud components that enable dynamic scaling and batch processing, allowing 4D to optimize run times and deliver rapid results. ...

By4D Path Inc.


4D Path Closes Latest Funding Round to Advance New Approach to Precise and Accelerated Cancer Diagnosis, Bringing Total to $6.4M

4D Path Closes Latest Funding Round to Advance New Approach to Precise and Accelerated Cancer Diagnosis, Bringing Total to $6.4M

Its platform is commercially available worldwide now to identify tumor-specific phenotypic and genotypic fingerprints that can inform treatment selection as well as stratify patients for novel targeted therapies without the need for a training dataset or human intervention. ...

By4D Path Inc.


Unbiased gene fusion analysis required in future cancer diagnostics

Unbiased gene fusion analysis required in future cancer diagnostics

The variation reflects cellular characteristics, or phenotype, and thus RNA analysis gives a more accurate view of the state cells in comparison to DNA analysis. ...

ByQlucore AB


Newly Published Study Proves Value and CliNewly Published Study Proves Value and Clinical Benefit of Daxor’s Blood Volume (BVA-100) Diagnostic in the Evaluationnical Benefit of Daxor’s Blood Volume (BVA-100) Diagnostic in the Evaluation of Heart Failure

Newly Published Study Proves Value and CliNewly Published Study Proves Value and Clinical Benefit of Daxor’s Blood Volume (BVA-100) Diagnostic in the Evaluationnical Benefit of Daxor’s Blood Volume (BVA-100) Diagnostic in the Evaluation of Heart Failure

The study titled, “Pressure-Volume Profiles in Heart Failure Across Sexes and Phenotypes,” assessed the relationship between cardiac filling pressures (a commonly used surrogate to assess blood volume) and total blood volume (TBV) measurement using Daxor’s BVA-100 blood test between sexes and left ventricular ejection fraction (LVEF), key clinical determinants ...

ByDaxor Corporation


ASH 2022: Cellworks Biosimulation Study Reveals Biomarkers that Predict Response to Hypomethylating Agents and Patient Survival in MDS

ASH 2022: Cellworks Biosimulation Study Reveals Biomarkers that Predict Response to Hypomethylating Agents and Patient Survival in MDS

Background Differentiation arrest resulting from aberrant methylation represents a key pathogenic and phenotypic feature of MDS. Hypomethylating agents (HMA) can reverse epigenetic dysregulation, but single agents fail to control the disease in approximately 50% of patients, many of whom progress to AML and carry a dismal prognosis. ...

ByCellworks Research India Private Limited


Molecular Devices adds proprietary patient-derived organoid technology with acquisition of Cellesce

Molecular Devices adds proprietary patient-derived organoid technology with acquisition of Cellesce

However, a number of retrospective studies confirm a high degree of similarity between the phenotype and genotype of a PDO and an original patient tumor, showing that if a drug worked on the PDO, it was 90 percent likely to work on the patient. ...

ByMolecular Devices, LLC.


Creative Proteomics Metabolomics Unveils Drug-Resistant Metabolomics Research Service

Creative Proteomics Metabolomics Unveils Drug-Resistant Metabolomics Research Service

Bacterial/fungal/viral/parasitic resistance studies: the metabolic state of bacteria is associated with a range of genetic and phenotypic resistance mechanisms. Thus, metabolomics is used to determine the relationship between antimicrobial resistance (AMR) mechanisms and microbial metabolism. 2. ...

ByCreative Proteomics


Elpiscience Announces Studies Presented at SITC 2022 Annual Meeting

Elpiscience Announces Studies Presented at SITC 2022 Annual Meeting

Title: ES009, a LILRB2-specific blocking antibody, reprograms myeloid cells into pro-inflammation phenotype and potentiates T cell activation Abstract No.: 1062 LILRB2 is predominantly expressed in myeloid lineage cells. ...

ByElpiscience


New Multi-Organ-Chip project towards vaccine & drug candidate testing for Tuberculosis

New Multi-Organ-Chip project towards vaccine & drug candidate testing for Tuberculosis

After airborne infection with Mycobacterium Tuberculosis, the new model system aims to show the disease-specific phenotype of “frustrated” phagocytosis, air-blood barrier damage, activated lymph node tissue and granuloma formation and maintenance. ...

ByTissUse GmbH


Altoida to Present at Upcoming Industry Conferences

Altoida to Present at Upcoming Industry Conferences

Altoida, Inc., the precision neurology company pioneering non-invasive brain health measurement and neurological disease diagnostics with AI and augmented reality (AR), today announced that management will be presenting at the upcoming conferences: BioFuture Panel Title: New Diagnostics: Revolutionizing Care in Alzheimer’s Date/Time: Wednesday, Nov. 9, 10:30 – 11:30 am ET Location: ...

ByAltoida, Inc.

  • Previous
  • Next
Need help finding the right suppliers?Try XPRT Sourcing. Let the XPRTs do the work for you
Back to top
About Medical XPRT

Medical XPRT is a global marketplace with solutions and suppliers for the medical sector, with product catalogs, articles, industry events, publications & more.

Channels

Solutions

  • Medical XPRT Industry Products
  • Medical XPRT Industry Software
  • Medical XPRT Industry Training
  • Medical XPRT Industry Services
  • Medical XPRT Industry Applications

Latest

  • Medical XPRT Industry News
  • Medical XPRT Industry Events

Publications

  • Medical XPRT Industry Articles
  • Medical XPRT Industry Books
  • Medical XPRT Industry Magazines
  • Medical XPRT Industry Downloads
  • Medical XPRT Industry Videos

Companies

  • Medical XPRT Industry Companies

  • FAQs
  • Company sitemap
  • Category sitemap
Medical XPRT is part of XPRT Media All Rights Reserved.
Terms
Privacy
  • Medical XPRT RSS List
Our sites:
Environmental XPRT
Agriculture XPRT
Energy XPRT
XPRT